CLINICAL_TRIALS
withdrawal
· 2026-02-20
Clinical Trial Update: ION-682884 in Patients With TTR Amyloid Cardiomyopathy [Phase 2]
Summary
A Phase 2 trial of ION-682884 for transthyretin amyloid cardiomyopathy has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Brigham and Women's Hospital | Conditions: Transthyretin Amyloid Cardiopathy | Phase 2 | Status: WITHDRAWN